Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 168

1.

Effects of paricalcitol on calcium and phosphate metabolism and markers of bone health in patients with diabetic nephropathy: results of the VITAL study.

Coyne DW, Andress DL, Amdahl MJ, Ritz E, de Zeeuw D.

Nephrol Dial Transplant. 2013 Sep;28(9):2260-8. doi: 10.1093/ndt/gft227. Epub 2013 Jun 19.

2.

Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.

Borrego Utiel FJ, Bravo Soto JA, Merino Pérez MJ, González Carmelo I, López Jiménez V, García Álvarez T, Acosta Martínez Y, Mazuecos Blanca MA.

Nefrologia. 2015;35(4):363-73. doi: 10.1016/j.nefro.2015.06.018. Epub 2015 Aug 4. English, Spanish.

3.

Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism.

Jamaluddin EJ, Gafor AH, Yean LC, Cader R, Mohd R, Kong NC, Shah SA.

Clin Exp Nephrol. 2014 Jun;18(3):507-14. doi: 10.1007/s10157-013-0844-2. Epub 2013 Aug 2.

PMID:
23903802
4.

19-Nor-1-alpha-25-dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis.

Martin KJ, González EA, Gellens M, Hamm LL, Abboud H, Lindberg J.

J Am Soc Nephrol. 1998 Aug;9(8):1427-32.

5.

Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.

Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S.

Nephrol Dial Transplant. 2014 Apr;29(4):899-905. doi: 10.1093/ndt/gfu011. Epub 2014 Feb 4.

PMID:
24500308
6.

A randomized multicenter trial of paricalcitol versus calcitriol for secondary hyperparathyroidism in stages 3-4 CKD.

Coyne DW, Goldberg S, Faber M, Ghossein C, Sprague SM.

Clin J Am Soc Nephrol. 2014 Sep 5;9(9):1620-6. doi: 10.2215/CJN.10661013. Epub 2014 Jun 26.

7.

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis.

Greenbaum LA, Benador N, Goldstein SL, Paredes A, Melnick JZ, Mattingly S, Amdahl M, Williams LA, Salusky IB.

Am J Kidney Dis. 2007 Jun;49(6):814-23.

PMID:
17533024
8.

Paricalcitol and endothelial function in chronic kidney disease trial.

Zoccali C, Curatola G, Panuccio V, Tripepi R, Pizzini P, Versace M, Bolignano D, Cutrupi S, Politi R, Tripepi G, Ghiadoni L, Thadhani R, Mallamaci F.

Hypertension. 2014 Nov;64(5):1005-11. doi: 10.1161/HYPERTENSIONAHA.114.03748. Epub 2014 Aug 4. Erratum in: Hypertension. 2015 Jun;65(6):e48.

9.

Effect of paricalcitol on circulating parathyroid hormone in X-linked hypophosphatemia: a randomized, double-blind, placebo-controlled study.

Carpenter TO, Olear EA, Zhang JH, Ellis BK, Simpson CA, Cheng D, Gundberg CM, Insogna KL.

J Clin Endocrinol Metab. 2014 Sep;99(9):3103-11. doi: 10.1210/jc.2014-2017. Epub 2014 Jul 16.

10.

Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.

Ross EA, Tian J, Abboud H, Hippensteel R, Melnick JZ, Pradhan RS, Williams LA, Hamm LL, Sprague SM.

Am J Nephrol. 2008;28(1):97-106. Epub 2007 Oct 3.

PMID:
17914251
11.

[Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].

Lorenzo Sellares V, Torregrosa V.

Nefrologia. 2008;28 Suppl 3:67-78. Spanish.

12.

Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients.

Dusilová-Sulková S, Šafránek R, Vávrová J, Horáček J, Pavlíková L, Palička V.

Int Urol Nephrol. 2015 Jan;47(1):169-76. doi: 10.1007/s11255-014-0842-7. Epub 2014 Sep 28.

PMID:
25262147
13.

Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.

Llach F, Yudd M.

Am J Kidney Dis. 2001 Nov;38(5 Suppl 5):S45-50.

PMID:
11689387
14.

Calcium balance during calcitriol and paricalcitol administration in healthy humans.

Hafner V, Rutsch C, Ding R, Heinrich T, Diedrichs L, Schmidt-Gayk H, Walter-Sack I, Bommer J, Mikus G.

Int J Clin Pharmacol Ther. 2008 Mar;46(3):131-5.

PMID:
18397683
15.

Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.

Fernström A, Giæver J, Granroth B, Hylander B, Jensen G, Christensson A, Wikström B, Weiss L, Wrege U, Jacobson SH.

Scand J Urol Nephrol. 2011 Apr;45(3):196-205. doi: 10.3109/00365599.2011.553738. Epub 2011 Mar 2.

PMID:
21366390
16.

Paricalcitol for secondary hyperparathyroidism in renal transplantation.

Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, Prandini S, Gaspari F, Cannata A, Villa A, Perna A, Gotti E, Caruso MR, Martinetti D, Remuzzi G, Perico N.

J Am Soc Nephrol. 2015 May;26(5):1205-14. doi: 10.1681/ASN.2013111185. Epub 2014 Sep 5.

17.

Beneficial effects of better control of secondary hyperparathyroidism with paricalcitol in chronic dialysis patients.

Capuano A, Serio V, Pota A, Memoli B, Andreucci VE.

J Nephrol. 2009 Jan-Feb;22(1):59-68.

PMID:
19229819
18.

Emerging role for the vitamin D receptor activator (VDRA), paricalcitol, in the treatment of secondary hyperparathyroidism.

Cozzolino M, Brancaccio D.

Expert Opin Pharmacother. 2008 Apr;9(6):947-54. doi: 10.1517/14656566.9.6.947. Review.

PMID:
18377338
19.

Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.

Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM.

Am J Kidney Dis. 2006 Feb;47(2):263-76.

PMID:
16431255
20.

A comparison of dosing regimens of paricalcitol capsule for the treatment of secondary hyperparathyroidism in CKD stages 3 and 4.

Abboud H, Coyne D, Smolenski O, Anger M, Lunde N, Qiu P, Hippensteel R, Pradhan RS, Palaparthy RV, Kavanaugh A, Melnick JZ, Williams LA, Batlle D.

Am J Nephrol. 2006;26(1):105-14. Epub 2006 Mar 14.

PMID:
16543714

Supplemental Content

Support Center